Drugs / TICOVAC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00161746 | Apr 1998 → Jun 1999 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01710189 | Oct 2012 → Oct 2014 | tick-borne encephalitis | University of Surrey | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-08-13 | Pfizer | Regulatory U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine pfizer.com ↗
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TICOVAC™ (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. |
| 2021-02-23 | Pfizer | Regulatory U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine) pfizer.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-08-13 | Pfizer | U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine pfizer.com ↗ |
| 2021-02-23 | Pfizer | U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine) pfizer.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TICOVAC | “after two and/or three partial vaccinations with TICOVAC 0.25 mL and TICOVAC 0.5 mL” NCT00161746 ↗ |
| Modality | Vaccine | “Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)” NCT00161746 ↗ |
| Route | Intramuscular | “Intramuscular immunisation to right deltoid muscle (Group 1) or right upper anterolateral thigh muscle (Group 2).” NCT01710189 ↗ |